Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225216 | 0.98 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL24673520 | 0.98 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL22837700 | 0.98 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL15535769 | 0.98 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL172303 | 0.93 | SIGMAR1 (0.38) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL22957162 | 0.91 | GGPS1 (0.46) | LMNAGGPS1S1PR2S1PR1S1PR3 | |
| SCHEMBL23948096 | 0.91 | GGPS1 (0.41) | LMNAKDM5AKDM4CGGPS1CHRM2 | |
| SCHEMBL5949010 | 0.90 | LMNA (0.48) | SIGMAR1LMNAKDM4CGGPS1CHRM2 | |
| SCHEMBL19364106 | 0.88 | GGPS1 (0.48) | LMNAGGPS1CHRM2S1PR2S1PR1 | |
| SCHEMBL8958562 | 0.88 | GGPS1 (0.48) | LMNAGGPS1CHRM2S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4180436-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20200375978-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375978-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SIGMAR1 3532/4885LMNA 1598/4885KDM5A 2143/4885 |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | SIGMAR1 4096/4885LMNA 3973/4885KDM5A 4039/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885LMNA 1656/4885KDM5A 197/4885 |
| US-20220409612-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | SIGMAR1 2827/4885LMNA 2058/4885KDM5A 3365/4885 |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR2, FPR1, FPR3 | SIGMAR1 990/4885LMNA 4108/4885KDM5A 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.